ReviewEndocrine2021
Will
Review in Endocrine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 87 citations in OpenAlex.
- First-line [European journal of nuclear medicine and molecular imaging · 2026Trial
- A novel imaging approach in hyperparathyroidism: [68Ga]Ga-Trivehexin PET/CT.European journal of nuclear medicine and molecular imaging · 2026Article
- Choline PET/CT in the PSMA Era: Clinical Repositioning, Biological Perspectives, and Emerging Applications.Diagnostics (Basel, Switzerland) · 2026Review
- FROM DISCOVERY SCIENCE TO THE CLINIC - HERITABLE ENDOCRINE CANCERS AND RELATED DISORDERS: Functional imaging in hereditary endocrine neoplasms: evolving modalities and clinical implications.Endocrine-related cancer · 2026Review
- Primary hyperparathyroidism: targeted, focused exploration with "selective" parathyroidectomy : Minimally invasive open vs. minimally invasive video-assisted vs. endoscopic approach.Wiener klinische Wochenschrift · 2026Review
- Preoperative localization in primary hyperparathyroidism: a stepwise approach integrating PTH-FNA washout and second-lineFrontiers in endocrinology · 2026Article
- Intrahepatic ectopic atypical parathyroid tumor causing primary hyperparathyroidism: a case report.Frontiers in medicine · 2026Article
- Structure-Encoded Location Biased Signaling in a Class B GPCR: Focus on the PTH Type 1 Receptor.Handbook of experimental pharmacology · 2026Review
- [European journal of nuclear medicine and molecular imaging · 2025Article
- Essentials for parathyroid imaging and intervention: what radiologists need to know.Ultrasonography (Seoul, Korea) · 2025Article
- Economic evaluation of [EJNMMI reports · 2025Article
- Article
- Contribution of 18 F-fluorocholine PET-CT to the preoperative localisation of parathyroid adenoma for the treatment of primary hyperparathyroidism.Scientific reports · 2025Article
- Refining the role of presurgical PET/4D-CT in a large series of patients with primary hyperparathyroidism undergoing [European journal of clinical investigation · 2025Article
- Comparison ofFrontiers in endocrinology · 2025Article
- Recurrent secondary hyperparathyroidism after parathyroidectomy due to anterior mediastinum ectopic parathyroid glands in a peritoneal dialysis patient-a case report and literature review.Frontiers in medicine · 2025Article
- Up-to-Date Imaging for Parathyroid Tumor Localization in MEN1 Patients with Primary Hyperparathyroidism: When and Which Ones (A Narrative Pictorial Review).Diagnostics (Basel, Switzerland) · 2024Review
- Cost-effectiveness of one-stop-shop [European journal of nuclear medicine and molecular imaging · 2024Article
- [European journal of nuclear medicine and molecular imaging · 2024Article
- Imaging Recommendations for Diagnosis and Management of Primary Parathyroid Pathologies: A Comprehensive Review.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrimary hyperparathyroidism (PHPT) is a common endocrine disorder usually due to hyperfunctioning parathyroid glands (HPs). Surgical removal of the HPs is the main treatment for PHPT, making the correct detection and localization of HPs crucial to guiding targeted and minimally invasive surgical treatment in patients with PHPT. To date, different imaging methods have been used to detect and localize HPs, including radiology, nuclear medicine, and hybrid techniques.
methodsThe present work discusses the role and value of different imaging methods in PHPT and, particularly, evaluates the potential role of DISCUSSION: Cervical ultrasound (US) and parathyroid scintigraphy using
conclusionsDue to the excellent diagnostic performance of radiolabeled choline PET/CT and the low radiation burden, this technique seems to be an ideal candidate to substitute current imaging procedures including US, MIBI scintigraphy, 4D CT and MRI and perform a fast and reliable "one-stop-shop" preoperative localization of HP in patients with PHPT, including challenging cases of postoperative persistent/recurrent disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.